EP2442819A4 - Behandlung von entzündungserkrankungen, herz-kreislauf-erkrankungen und akutem ischämischem schlaganfall mit ozon - Google Patents

Behandlung von entzündungserkrankungen, herz-kreislauf-erkrankungen und akutem ischämischem schlaganfall mit ozon

Info

Publication number
EP2442819A4
EP2442819A4 EP10789881A EP10789881A EP2442819A4 EP 2442819 A4 EP2442819 A4 EP 2442819A4 EP 10789881 A EP10789881 A EP 10789881A EP 10789881 A EP10789881 A EP 10789881A EP 2442819 A4 EP2442819 A4 EP 2442819A4
Authority
EP
European Patent Office
Prior art keywords
ozone
acoustic
treatment
cardiovascular diseases
inflammatory disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10789881A
Other languages
English (en)
French (fr)
Other versions
EP2442819A2 (de
Inventor
Joseph S Latino
Steven A Keyser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acquisci Inc
Original Assignee
Acquisci Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acquisci Inc filed Critical Acquisci Inc
Priority claimed from US12/819,875 external-priority patent/US20100316730A1/en
Priority claimed from US12/819,886 external-priority patent/US20100316727A1/en
Priority claimed from US12/819,871 external-priority patent/US20100318014A1/en
Publication of EP2442819A2 publication Critical patent/EP2442819A2/de
Publication of EP2442819A4 publication Critical patent/EP2442819A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10789881A 2009-06-19 2010-06-21 Behandlung von entzündungserkrankungen, herz-kreislauf-erkrankungen und akutem ischämischem schlaganfall mit ozon Withdrawn EP2442819A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26909009P 2009-06-19 2009-06-19
US26909109P 2009-06-19 2009-06-19
US26908709P 2009-06-19 2009-06-19
US12/819,875 US20100316730A1 (en) 2003-07-31 2010-06-21 Treatment of cardiovascular diseases with ozone
US12/819,886 US20100316727A1 (en) 2003-07-31 2010-06-21 Treatment of inflammatory disorders with ozone
PCT/US2010/001785 WO2010147677A2 (en) 2009-06-19 2010-06-21 Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone
US12/819,871 US20100318014A1 (en) 2003-07-31 2010-06-21 Treatment of acute ischemic brain stroke with ozone

Publications (2)

Publication Number Publication Date
EP2442819A2 EP2442819A2 (de) 2012-04-25
EP2442819A4 true EP2442819A4 (de) 2013-01-02

Family

ID=43356980

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10789881A Withdrawn EP2442819A4 (de) 2009-06-19 2010-06-21 Behandlung von entzündungserkrankungen, herz-kreislauf-erkrankungen und akutem ischämischem schlaganfall mit ozon

Country Status (5)

Country Link
EP (1) EP2442819A4 (de)
AU (1) AU2010260467A1 (de)
CA (1) CA2765479A1 (de)
IN (1) IN2012DN00534A (de)
WO (1) WO2010147677A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3500277A4 (de) * 2016-08-19 2020-04-15 Immunores-Therapeutics, LLC Freisetzungssysteme und verfahren für gasbehandlung
WO2018035504A1 (en) 2016-08-19 2018-02-22 Lane Ronald Howard Gas treatment delivery systems and methods

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067764A2 (en) * 1999-05-06 2000-11-16 Vasogen Inc. Improved method for treating mammals with modified mammalian blood
WO2001085185A2 (en) * 2000-05-11 2001-11-15 Vasogen Ireland Limited Treatment of il-10 deficiencies
US20020051766A1 (en) * 2000-01-18 2002-05-02 Smith Eldon R. Treatment of congestive heart failure
WO2002080945A2 (en) * 2001-04-06 2002-10-17 Vasogen Ireland Limited Methods for treating the inflammatory component of a brain disorder
US20050051498A1 (en) * 2003-07-31 2005-03-10 Latino Joseph S. Ozone delivery system including gas-fluid contacting devices and methods of use
WO2006007710A2 (en) * 2004-07-20 2006-01-26 Vasogen Ireland Limited Acute inflammatory condition treatment
WO2007115398A1 (en) * 2006-04-10 2007-10-18 Vasogen Ireland Limited Treatment of elevated c-reactive protein levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0414093A (pt) * 2003-09-05 2006-10-31 Scripps Res Insittute produtos de ozonização de colesterol para o tratamento e prevenção de ateroesclerose e/ou doenças cardiovasculares
JP2005348774A (ja) * 2004-06-08 2005-12-22 Masako Negishi 動物の病気の治療方法とそのための治療装置
US20060210644A1 (en) * 2004-12-16 2006-09-21 Bruce Levin Materials, methods, and devices for treatment of arthropathies and spondylopathies
EP1932524A1 (de) * 2006-12-13 2008-06-18 Ludwig-Maximilians-Universität München Pharmazeutische Präparate zur Behandlung von Entzündungserkrankungen

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067764A2 (en) * 1999-05-06 2000-11-16 Vasogen Inc. Improved method for treating mammals with modified mammalian blood
US20020051766A1 (en) * 2000-01-18 2002-05-02 Smith Eldon R. Treatment of congestive heart failure
WO2001085185A2 (en) * 2000-05-11 2001-11-15 Vasogen Ireland Limited Treatment of il-10 deficiencies
WO2002080945A2 (en) * 2001-04-06 2002-10-17 Vasogen Ireland Limited Methods for treating the inflammatory component of a brain disorder
US20050051498A1 (en) * 2003-07-31 2005-03-10 Latino Joseph S. Ozone delivery system including gas-fluid contacting devices and methods of use
WO2006007710A2 (en) * 2004-07-20 2006-01-26 Vasogen Ireland Limited Acute inflammatory condition treatment
WO2007115398A1 (en) * 2006-04-10 2007-10-18 Vasogen Ireland Limited Treatment of elevated c-reactive protein levels

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUTTKE T M ET AL: "OXIDATIVE STRESS AS A MEDIATOR OF APOPTOSIS", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 15, no. 1, 1 January 1994 (1994-01-01), pages 7 - 10, XP000673595, ISSN: 0167-5699, DOI: 10.1016/0167-5699(94)90018-3 *
SAEID BABAEI ET AL: "Effects of VasoCare(TM) therapy on the initiation and progression of atherosclerosis", ATHEROSCLEROSIS, vol. 162, no. 1, 1 May 2002 (2002-05-01), pages 45 - 53, XP055045754, ISSN: 0021-9150, DOI: 10.1016/S0021-9150(01)00680-3 *
See also references of WO2010147677A2 *

Also Published As

Publication number Publication date
WO2010147677A3 (en) 2011-05-12
EP2442819A2 (de) 2012-04-25
CA2765479A1 (en) 2010-12-23
AU2010260467A1 (en) 2012-02-09
WO2010147677A2 (en) 2010-12-23
IN2012DN00534A (de) 2015-06-05

Similar Documents

Publication Publication Date Title
FR20C1014I2 (fr) Traitement de troubles du cycle sommeil-eveil
EP2340242A4 (de) Verbindungen zur behandlung von augenerkrankungen und -leiden
EP2056673A4 (de) Kombinationsbehandlung für stoffwechselerkrankungen
EP1885388A4 (de) Behandlung und beurteilung von entzündlichen erkrankungen
EP2152865A4 (de) Verfahren zur behandlung und vorbeugung neurodegenerativer krankheiten und störungen
EP2282795A4 (de) Behandlung von atemwegserkrankungen
EP2911664A4 (de) Kombinationstherapien zur behandlung von morbus alzheimer und verwandten erkrankungen
EP2389227A4 (de) Verfahren zur behandlung von akuten myokardinfarkten und damit assoziierten erkrankungen
LT3135672T (lt) Kompozicijos ir būdai skirti gydyti alkoholio vartojimo sutrikimus, skausmą ir kitas ligas
EP2691102A4 (de) Pflanzliche zusammensetzungen zur behandlung neurologischer krankheiten und zur linderung von gedächtnisstörungen
EP2375907A4 (de) Behandlung von krankheiten, störungen oder leiden der lunge mittels plazentazellen
EP2414521A4 (de) Regulierung von mir-33-mikrornas bei der behandlung cholesterinspiegelbedingter erkrankungen
EP2470553A4 (de) Polyhydroylierte gallensäure zur behandlung von gallenerkrankungen
EP2285347A4 (de) Zusammensetzungen und verfahren zur behandlung von erkrankungen des verdauungssystems
EP2038004A4 (de) Behandlung neurologischer erkrankungen mittels elektrostimulation und entsprechende verfahren
EP2726511A4 (de) Zusammensetzungen, verwendungen davon und verfahren zur behandlung von stoffwechselerkrankungen und -leiden
EP2273882A4 (de) Bioaktive verbindungen zur behandlung von krebs und neurodegenerativen erkrankungen
EP2877184A4 (de) Zusammensetzungen und behandlungsverfahren für augenerkrankungen und störungen
EP2176283A4 (de) Verfahren und zusammensetzungen zur behandlung von hirnerkrankungen
EP2349282A4 (de) Verfahren zur behandlung von lungenerkrankungen mit liposomalen amikacinformulierungen
EP2433622A4 (de) Mittel zur prophylaxe und behandlung in hohem masse pathogener infektionskrankheiten
EP2323641A4 (de) Nyasol und analoge davon zur behandlung von östrogen-rezeptor-beta-vermittelten erkrankungen
EP2763540A4 (de) Zusammensetzungen und verfahren zur beurteilung und behandlung von entzündlichen krankheiten und erkrankungen
EP2247297A4 (de) Therapeutische behandlung von lungenerkrankungen
EP2408740A4 (de) Verbindungen zur behandlung von entzündungen und schmerzen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120119

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20121204

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20121128BHEP

Ipc: A61P 29/00 20060101ALI20121128BHEP

Ipc: A61K 33/40 20060101AFI20121128BHEP

Ipc: A61P 19/02 20060101ALI20121128BHEP

Ipc: A61P 25/28 20060101ALI20121128BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170102

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250509